Obstructive sleep apnea: A cardiometabolic risk in obesity and the metabolic syndrome

Luciano F. Drager, Sônia M. Togeiro, Vsevolod Polotsky, Geraldo Lorenzi-Filho

Research output: Contribution to journalArticle

Abstract

Obstructive sleep apnea (OSA) is an underdiagnosed condition characterized by recurrent episodes of obstruction of the upper airway leading to sleep fragmentation and intermittent hypoxia during sleep. Obesity predisposes to OSA, and the prevalence of OSA is increasing worldwide because of the ongoing epidemic of obesity. Recent evidence has shown that surrogate markers of cardiovascular risk, including sympathetic activation, systemic inflammation, and endothelial dysfunction, are significantly increased in obese patients with OSA versus those without OSA, suggesting that OSA is not simply an epiphenomenon of obesity. Moreover, findings from animal models and patients with OSA show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and nonalcoholic fatty liver disease. In patients with the metabolic syndrome, the prevalence of moderate to severe OSA is very high (∼60%). In this population, OSA is independently associated with increased glucose and triglyceride levels as well as markers of inflammation, arterial stiffness, and atherosclerosis. A recent randomized, controlled, crossover study showed that effective treatment of OSA with continuous positive airway pressure for 3 months significantly reduced several components of the metabolic syndrome, including blood pressure, triglyceride levels, and visceral fat. Finally, several cohort studies have consistently shown that OSA is associated with increased cardiovascular mortality, independent of obesity. Taken together, these results support the concept that OSA exacerbates the cardiometabolic risk attributed to obesity and the metabolic syndrome. Recognition and treatment of OSA may decrease the cardiovascular risk in obese patients.

Original languageEnglish (US)
Pages (from-to)569-576
Number of pages8
JournalJournal of the American College of Cardiology
Volume62
Issue number7
DOIs
StatePublished - Aug 13 2013

Fingerprint

Obstructive Sleep Apnea
Obesity
Triglycerides
Inflammation
Vascular Stiffness
Continuous Positive Airway Pressure
Sleep Deprivation
Intra-Abdominal Fat
Airway Obstruction
Cross-Over Studies
Insulin Resistance
Atherosclerosis
Sleep
Cohort Studies
Animal Models
Biomarkers

Keywords

  • cardiovascular risk
  • metabolic syndrome
  • obesity
  • sleep apnea

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Obstructive sleep apnea : A cardiometabolic risk in obesity and the metabolic syndrome. / Drager, Luciano F.; Togeiro, Sônia M.; Polotsky, Vsevolod; Lorenzi-Filho, Geraldo.

In: Journal of the American College of Cardiology, Vol. 62, No. 7, 13.08.2013, p. 569-576.

Research output: Contribution to journalArticle

Drager, Luciano F. ; Togeiro, Sônia M. ; Polotsky, Vsevolod ; Lorenzi-Filho, Geraldo. / Obstructive sleep apnea : A cardiometabolic risk in obesity and the metabolic syndrome. In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 7. pp. 569-576.
@article{2c74c21acd8a495d83b5cb9f191c6be9,
title = "Obstructive sleep apnea: A cardiometabolic risk in obesity and the metabolic syndrome",
abstract = "Obstructive sleep apnea (OSA) is an underdiagnosed condition characterized by recurrent episodes of obstruction of the upper airway leading to sleep fragmentation and intermittent hypoxia during sleep. Obesity predisposes to OSA, and the prevalence of OSA is increasing worldwide because of the ongoing epidemic of obesity. Recent evidence has shown that surrogate markers of cardiovascular risk, including sympathetic activation, systemic inflammation, and endothelial dysfunction, are significantly increased in obese patients with OSA versus those without OSA, suggesting that OSA is not simply an epiphenomenon of obesity. Moreover, findings from animal models and patients with OSA show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and nonalcoholic fatty liver disease. In patients with the metabolic syndrome, the prevalence of moderate to severe OSA is very high (∼60{\%}). In this population, OSA is independently associated with increased glucose and triglyceride levels as well as markers of inflammation, arterial stiffness, and atherosclerosis. A recent randomized, controlled, crossover study showed that effective treatment of OSA with continuous positive airway pressure for 3 months significantly reduced several components of the metabolic syndrome, including blood pressure, triglyceride levels, and visceral fat. Finally, several cohort studies have consistently shown that OSA is associated with increased cardiovascular mortality, independent of obesity. Taken together, these results support the concept that OSA exacerbates the cardiometabolic risk attributed to obesity and the metabolic syndrome. Recognition and treatment of OSA may decrease the cardiovascular risk in obese patients.",
keywords = "cardiovascular risk, metabolic syndrome, obesity, sleep apnea",
author = "Drager, {Luciano F.} and Togeiro, {S{\^o}nia M.} and Vsevolod Polotsky and Geraldo Lorenzi-Filho",
year = "2013",
month = "8",
day = "13",
doi = "10.1016/j.jacc.2013.05.045",
language = "English (US)",
volume = "62",
pages = "569--576",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "7",

}

TY - JOUR

T1 - Obstructive sleep apnea

T2 - A cardiometabolic risk in obesity and the metabolic syndrome

AU - Drager, Luciano F.

AU - Togeiro, Sônia M.

AU - Polotsky, Vsevolod

AU - Lorenzi-Filho, Geraldo

PY - 2013/8/13

Y1 - 2013/8/13

N2 - Obstructive sleep apnea (OSA) is an underdiagnosed condition characterized by recurrent episodes of obstruction of the upper airway leading to sleep fragmentation and intermittent hypoxia during sleep. Obesity predisposes to OSA, and the prevalence of OSA is increasing worldwide because of the ongoing epidemic of obesity. Recent evidence has shown that surrogate markers of cardiovascular risk, including sympathetic activation, systemic inflammation, and endothelial dysfunction, are significantly increased in obese patients with OSA versus those without OSA, suggesting that OSA is not simply an epiphenomenon of obesity. Moreover, findings from animal models and patients with OSA show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and nonalcoholic fatty liver disease. In patients with the metabolic syndrome, the prevalence of moderate to severe OSA is very high (∼60%). In this population, OSA is independently associated with increased glucose and triglyceride levels as well as markers of inflammation, arterial stiffness, and atherosclerosis. A recent randomized, controlled, crossover study showed that effective treatment of OSA with continuous positive airway pressure for 3 months significantly reduced several components of the metabolic syndrome, including blood pressure, triglyceride levels, and visceral fat. Finally, several cohort studies have consistently shown that OSA is associated with increased cardiovascular mortality, independent of obesity. Taken together, these results support the concept that OSA exacerbates the cardiometabolic risk attributed to obesity and the metabolic syndrome. Recognition and treatment of OSA may decrease the cardiovascular risk in obese patients.

AB - Obstructive sleep apnea (OSA) is an underdiagnosed condition characterized by recurrent episodes of obstruction of the upper airway leading to sleep fragmentation and intermittent hypoxia during sleep. Obesity predisposes to OSA, and the prevalence of OSA is increasing worldwide because of the ongoing epidemic of obesity. Recent evidence has shown that surrogate markers of cardiovascular risk, including sympathetic activation, systemic inflammation, and endothelial dysfunction, are significantly increased in obese patients with OSA versus those without OSA, suggesting that OSA is not simply an epiphenomenon of obesity. Moreover, findings from animal models and patients with OSA show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and nonalcoholic fatty liver disease. In patients with the metabolic syndrome, the prevalence of moderate to severe OSA is very high (∼60%). In this population, OSA is independently associated with increased glucose and triglyceride levels as well as markers of inflammation, arterial stiffness, and atherosclerosis. A recent randomized, controlled, crossover study showed that effective treatment of OSA with continuous positive airway pressure for 3 months significantly reduced several components of the metabolic syndrome, including blood pressure, triglyceride levels, and visceral fat. Finally, several cohort studies have consistently shown that OSA is associated with increased cardiovascular mortality, independent of obesity. Taken together, these results support the concept that OSA exacerbates the cardiometabolic risk attributed to obesity and the metabolic syndrome. Recognition and treatment of OSA may decrease the cardiovascular risk in obese patients.

KW - cardiovascular risk

KW - metabolic syndrome

KW - obesity

KW - sleep apnea

UR - http://www.scopus.com/inward/record.url?scp=84881341125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881341125&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.05.045

DO - 10.1016/j.jacc.2013.05.045

M3 - Article

C2 - 23770180

AN - SCOPUS:84881341125

VL - 62

SP - 569

EP - 576

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -